Drug Profile
Aliskiren - Noden Pharma
Alternative Names: Aliskiren fumarate; Aliskiren hemi-fumarate; CGP 60536B; Enviage™; Rasilez; Rasilles; Riprazo™; SPP 100; SPP 100B; Sprimeo™; TekturnaLatest Information Update: 23 Sep 2021
Price :
$50
*
At a glance
- Originator Novartis
- Class Amides; Antihypertensives; Fumarates; Small molecules
- Mechanism of Action Renin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hypertension
- Discontinued Acute heart failure; Atherosclerosis; Chronic heart failure; Diabetic macular oedema; Diabetic nephropathies; Kidney disorders; Myocardial infarction
Most Recent Events
- 10 Apr 2021 Discontinued - Phase-III for Chronic heart failure in Mexico, Costa Rica, Turkey, South Africa, Thailand, Japan, United Kingdom, Taiwan, Brazil, South Korea, Spain, Dominican Republic, Austria, Latvia, Switzerland, Romania, Dominican Republic, Czech Republic, Estonia, Russia, Belgium, Peru, South Korea, USA, Puerto Rico, Australia, Greece, Colombia, Argentina, India, Canada, China, France, Norway, Lithuania, Sweden, Slovakia, Netherlands, Venezuela, Ireland, Finland, Denmark, Germany, Italy, Poland, Portugal (PO)
- 28 Sep 2020 Launched in Hypertension in Greece (PO, Tablets)
- 07 Jul 2020 Launched in Hypertension in Hungary (PO, Tablets)